ArticleFrontiers in immunology2026
Exosomal POSTN from cancer-associated fibroblasts drives progression of microinvasive lung adenocarcinoma: insights from single-cell and tissue exosome sequencing analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microinvasive adenocarcinoma (MIA) represents an early stage of lung adenocarcinoma (LUAD), yet how the tumor microenvironment (TME) and cancer-associated fibroblast (CAF)-derived exosomes contribute to its progression remains unclear. We aimed to define the cellular ecosystem of MIA and to clarify the role of periostin (POSTN) and POSTN Methods: Single-cell RNA sequencing (scRNA-seq) and tissue-derived exosomal RNA sequencing were performed on four primary MIA lesions and matched adjacent lung tissues. Integrated analyses of scRNA-seq data, exosomal transcriptomes, the TCGA-LUAD cohort, and an independent LUAD tissue/serum cohort were used to characterize POSTN expression and to evaluate its prognostic and diagnostic relevance. Primary MIA-associated POSTN Results: scRNA-seq identified a malignant Cancer-alveolar type II (Cancer-AT2) epithelial subset and multiple CAF subsets. Among these, POSTN Conclusion: Exosomal POSTN derived from POSTN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.